Inside the Lab is joined by experts Drs. Hannah Wang from the Cleveland Clinic and Rodney Rohde from Texas State University to discuss emerging respiratory viruses. Their discussion begins with lessons learned from the COVID-19 pandemic and an overview of what technologies have emerged since. They go on to discuss the virology and surveillance strategies for H5N1 and RSV, as well as vaccine hesitancy and its impact in the treatment of measles.

In this episode of Inside the Lab, Dr. Ali Brown sits down with guests Sean Tucker, MLS(ASCP)CM and Laura Severs, MHA, MLS(ASCP)CM to discuss their predictions for what 2025 holds for laboratory professionals. Topics discussed include:

• How workforce trends will continue in the near future and what strategies may work for addressing them;
• What to expect with automation and what pros and cons automation holds for Labradorians;
• What challenges, risks, and benefits cybersecurity holds for laboratory professionals, particular as digital pathology becomes more prevalent;
• What's coming with AI and what it means for the practice of laboratory medicine.

In this episode of Inside the Lab, guests Jane Dickerson, PhD and Elise Occhipinti, MD join host Kelly Swails to discuss the creation and maintenance of laboratory test stewardship programs. Topics covered include:

• How and why your organization should set up a stewardship program
• Involving stakeholders in the process
• The essential components of a success program
• Metrics and key performance indicators to track
• Resources, guidelines, and toolkits for those looking to create their own program

While the rapid evolution of I-O continues to bring unprecedented change to the way cancer is treated, there are significant gaps impacting the laboratory team regarding the examination of resection specimens following neoadjuvant immunotherapy and staying abreast of advances in I-O biomarker testing.

This episode discusses advances in I-O biomarker testing, advantages and limitations of some key I-O biomarkers, and practical ways that pathologists and laboratory professionals can improve their I-O biomarker testing workflows to optimize patient care.

Topics discussed include:

• Recent advances in immune-oncology (I-O) biomarker testing
• Advantages and limitations of IO biomarkers
• Addressing challenges related to IO biomarkers
• Improving IO biomarker workflows
• Best practices for collaboration with the multidisciplinary cancer care team

The diagnostic paradigm for Alzheimer's disease (AD) has rapidly shifted in the last five years as fluid-based biomarker testing has emerged as a reliable, accurate, and accessible means to detect amyloid pathology when evaluating a patient for cognitive decline. This podcast is designed to help pathologists and laboratory professionals gain an understanding of plasma testing for markers such as Abeta40/42, P-tau181, and P-tau217 which are rapidly appearing in the commercial space and how healthcare providers have begun incorporating these tests into routine neurology practice. This podcast will help participants to understand the advantages and limitations of these assays as well as their potential application when a physician is evaluating a patient for AD.

Communicating imperative diagnoses effectively can often be a daunting challenge. It’s a crucial and delicate step that takes practice and know-how to do well and can be one of the most important actions taken with patients. That’s why a panel of experts have gotten together to discuss the current practices, gaps, and best practices for communication of urgent and significant/unexpected diagnoses in anatomic pathology.

The Promoting Diagnostic Excellence by Improving the Communication of Urgent and Unexpected Diagnoses in Anatomic Pathology podcast is designed to support the collaboration with clinical partners as well as to notice actionable opportunities where the communication of urgent and significant/unexpected diagnoses in anatomic pathology may be improved.

You will learn to:

• Understand current guidelines and practices for communication of urgent and unexpected diagnosis in anatomic pathology.
• Discuss high-priority communication barriers.
• Discuss best practices and recommendations for effective and timely communication of urgent and significant/unexpected diagnoses.

Women make up a majority of the workforce in pathology yet lag behind men in leadership roles. What are the consequences of this for women working in pathology today, and what can be done?

In this episode of Inside the Lab, Drs. Melissa Upton and Kimberly Sanford share a warm conversation in which they reflect on their long and varied careers, describe the unique challenges they faced over their careers, and discuss their accomplishments as trailblazers themselves. Our guests describe the value of finding mentors, They also describe the opportunities for the future of pathology, particularly in the context of working in a multigenerational workforce with evolving expectations of workplace culture.

Although molecular testing offers promising opportunities for diagnosis and targeted treatment of cancers, prostate cancer has lagged behind other types of cancer. Recently, homologous recombination repair testing in prostate cancer has provided a means to achieving targeted treatments for patients as well as opening new avenues of collaboration between pathologists and oncologists.

On this episode of Inside the Lab, hosts Ms. Kelly Swails, MLS(ASCP), and Dr. Ali Brown, MD, FASCP are joined by Heather Cheng, a medical oncologist and associate professor of hematology and oncology at the University of Washington and Fred Hutchinson Cancer Center, and Colin Pritchard, molecular pathologist and professor of laboratory science and director of the Genetics and Solid Tumors Laboratory at the University of Washington Medical Center.

Our panelists discuss the current treatment landscape for prostate cancer and how HRR testing can improve patient outcomes in this context.

Topics Covered

• An introduction to metastatic prostate cancer testing, and what types of tests are standard of care, and the rationale for targeting prostate cancer using PARP
• Key findings from recent phase III randomized clinical trials
• Standards for optimal testing in prostate cancer, particularly concerning sample sources and the choice between next-generation sequencing (NGS) and polymerase chain reaction (PCR) methods
• common pitfalls or challenges in the arena of accurately reporting and interpreting findings from HRR tests
• Practical tips for optimal coordination among a multidisciplinary, cross-departmental team of healthcare providers and laboratory professionals when utilizing HRR testing in prostate cancer management.

Connect with ASCP
ASCP
ASCP on Facebook
ASCP on Instagram
ASCP on Twitter

Connect with Dr. Cheng
Dr. Cheng on LinkedIn

Connect with Dr. Pritchard
Dr. Pritchard

Connect with Ms. Swails & Dr. Brown
Ms. Swails on Twitter
Dr. Brown on Twitter

Resources
ASCP Membership 2024
Proposed FDA Regulation of Laboratory Developed Tests
Public Comment on the FDA’s Proposed Rule
Inside the Lab in the ASCP Store